Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated

CORTNYSE / NASDAQHealthcareMid cap

$63.62-$1.36 (-2.1%)

Last close · Data as of Nov 20, 2026

Market cap
$8.0B
P/E
80.7x
EV / EBITDA
66.1x
Revenue
$761.4M
Net margin
13.1%
ROCE
6.7%

This period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Corcept Therapeutics Incorporated price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-45.4%
3M
-47.4%
6M
+7.7%
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$1.36 (-2.1%) from $64.98 to $63.62 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CORT, bought on each weekday since 2021.

News & filings

What Corcept Therapeutics Incorporated filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating margin fell for three years, from 22.2% to 5.9%.

Strengths (1)

  • Return on equity of 15.4% against a peer median of 8.0%.
  • This period includes a one-day price step on 31 Dec 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

Read moreShow less

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Sector
Healthcare
Shares outstanding
104.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$8.0B
P/E
80.7x
P/B
12.4x
EV / EBITDA
66.1x
EV / Sales
10.4x
P/S
10.6x
52-week high
Hidden
52-week low
Hidden

Profitability

Operating margin
5.9%
Net margin
13.1%
EBITDA margin
15.2%
ROE
15.4%
ROCE
6.7%
ROA
11.9%
Asset turnover
0.91

Growth

Revenue
$761.4M
Revenue growth, 1Y
12.8%
Revenue CAGR, 3Y
23.7%
Net profit growth, 1Y
-29.4%
Free cash flow
$141.8M

Solvency

Current ratio
2.92
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
1.42
Cash / Market cap
1.5%

Where the revenue went

Of every $100 of FY2025 revenue, $13 was left as net income.

Corcept Therapeutics Incorporated income statement flow, FY2025
Corcept Therapeutics Incorporated income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$13.0M
RevenueGross profit$748.4M
Gross profitResearch and development$254.9M
Gross profitSelling, general and administrative$448.7M
Gross profitOperating income$44.8M
Operating incomePretax income$44.8M
Interest and other incomePretax income$21.7M
Pretax incomeNet income$66.5M
Tax benefit and otherNet income$33.2M

Revenue and net profit

Revenue grew 12.8% in FY2025; net profit is the dashed line.

Corcept Therapeutics Incorporated revenue and net profit by fiscal year
Corcept Therapeutics Incorporated revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$401.9M$101.4M
FY2023$482.4M$106.1M
FY2024$675.0M$141.2M
FY2025$761.4M$99.7M

Cash flows

FY2025: $142.0M from operations, $141.8M free after investment (dashed).

Corcept Therapeutics Incorporated operating and free cash flow by fiscal year
Corcept Therapeutics Incorporated operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$120.3M$119.9M
FY2023$126.7M$126.5M
FY2024$198.3M$196.1M
FY2025$142.0M$141.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$761.4M+12.8%1Y
Net profit
$99.7M-29.4%1Y
Cash from operations
$142.0M-28.4%1Y
Free cash flow
$141.8M-27.7%1Y
Revenue CAGR, 3Y
23.7%
Net profit CAGR, 3Y
-0.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$761.4M—$99.7M$141.8M15.4%+12.8%-29.4%

Monthly returns

Month-by-month returns of CORT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$836.6M
Liabilities$188.8M
Equity$647.8M
Paid-in capital$968.6M
Retained earnings$643.4M
Treasury stock$966.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CORT highlighted.

P/E against peers

CORT trades at 80.7x earnings against a peer median of 21.8x (a 269% premium).

  1. Corcept Therapeutics Incorporated (this company)80.7x

Not shown (no positive earnings and no EV / Sales): Charles River Laboratories International, Inc., Glaukos Corporation, Protagonist Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Corcept Therapeutics IncorporatedCORTthis companyP/E ↑ premium$8.0B80.7x12.4x15.4%66.1x
Krystal Biotech, Inc.KRYS$9.1B44.3x7.4x16.8%51.2x
Charles River Laboratories International, Inc.CRL$8.9B—2.8x-4.6%27.5x
Henry Schein, Inc.HSIC$8.7B21.8x2.7x12.3%12.4x
Bio-Techne CorporationTECH$8.3B113.5x4.3x3.8%39.7x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Protagonist Therapeutics, Inc.PTGX$6.6B-50.8x10.8x-21.2%-41.4x
TG Therapeutics, Inc.TGTX$6.2B13.9x9.6x69.0%47.5x
Peer median—21.8x5.9x8.0%24.2x

Year-to-date ROI

CORT since 1 January, against earlier years.

Historical volatility

CORT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Corcept Therapeutics Incorporated operating margin by fiscal year
Corcept Therapeutics Incorporated operating margin by fiscal year
DateOperating margin
FY202228.0%
FY202322.2%
FY202420.3%
FY20255.9%
LineFY2025
Cost of revenueCost Of Revenue$13.0M
Gross profitGross Profit$748.4M
Operating expensesOperating Expense$703.6M
Research and developmentResearch And Development$254.9M
Selling, general and administrativeSelling General And Administration$448.7M
Total expensesTotal Expenses$716.6M
Pretax incomePretax Income$66.5M

Learn while you research

Academy chapters picked for Corcept Therapeutics Incorporated and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 80.7, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →